TOKYO--( / ) May 07, 2014 -- Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the European Commission has granted a marketing authorization for Deltyba™ (delamanid) for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.
Deltyba is a bactericidal agent with a novel mode of action that interferes with the metabolism of the Mycobacterium tuberculosis (MTB) cell walls. It also has high activity in vitro against various MTB strains, including those resistant to first-line anti-TB drugs, such as isoniazid and rifampicin.
Deltyba was designated as an orphan medicine in 2008 meaning that it is a medicine used to treat a rare disease. Clinical trial results from 9 countries showed that study subjects treated with Deltyba 100mg twice daily together with an optimized background regimen (OBR) achieved a statistically significant increase in sputum culture conversion (SCC) after two months (45.4% of study subjects) compared to those treated with a placebo (29.6% of study subjects). SCC is a measurement used to determine when a patient is no longer infectious.
Akihiko Otsuka, Chairman of Otsuka, stated, “It is very pleasing to me that a new drug developed by Otsuka Pharmaceutical has become available to patients in Europe with MDR-TB. Currently, MDR-TB is a serious problem there. When rifampicin was developed half a century ago, it seemed that the world’s TB problem was over. But I specifically selected TB as a research theme for our company. I knew that someone had to do this research because TB was still a huge public health issue in Asia.”
Resistance to anti-TB drugs can occur for a number of reasons including misuse or mismanagement, such as failure to complete a full course of treatment due to potential side effects. The emergence of MDR-TB has become a major global concern imposing a burden on patients to comply with treatment regimens that can last for a minimum of 20 months. With a treatment success rate of less than 50% globally, the treatment of MDR-TB patients using only existing anti-TB drugs has created an urgent unmet medical need.
“The TB community has waited a long time for a new medication for MDR-TB,” said Dr. Wiel de Lange, an MDR-TB expert at the University Medical Center in Groningen, the Netherlands. “With increasing rates of resistance to existing medications and globally less than half of all MDR-TB cases successfully treated, Deltyba is clearly a welcome new option.”
Taro Iwamoto, President of Otsuka Pharmaceutical, commented, “I am very gratified that Deltyba has been granted a marketing authorization as a first-in-class, anti-TB drug in Europe - a dream we have held since the establishment of our research institute. There are still many patients throughout the world who suffer from MDR-TB. I hope Deltyba will contribute to the improvement of TB treatment.”
To ensure that in the future patients can continue to benefit from Deltyba, Otsuka has invested in the creation of a Responsible Access Programme (RAP) to help safeguard against the possible emergence of resistance to the medicine. The RAP includes strict distribution control, professional medical education about the proper administration of Deltyba in combination with other MDR-TB drugs, and a comprehensive patient registry to track the safety and efficacy of Deltyba. Otsuka remains committed to providing access to Deltyba in underserved populations and will apply for marketing authorization in high burden countries and countries in which clinical trials have taken place.
Deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. The recommended dose for adults is 100 mg twice daily for 24 weeks. Clinical trial results showed 45.4% of study subjects treated with Deltyba 100 mg twice daily plus OBR, achieved sputum culture conversion (SCC), a measurement by which a patient is no longer infectious, after two months compared to 29.6% of those treated with placebo plus OBR, representing a statistically significant 53% increase.
Clinical trial results demonstrated that adverse events were evenly distributed in the Deltyba and placebo treatment groups with the exception of QT prolongation. Electrocardiogram QT prolongation was reported in 9.9% of patients receiving Deltyba as 100 mg twice daily compared to 3.8% of patients receiving placebo plus OBR. This was not accompanied by any clinical symptoms such as syncope or arrhythmias.
According to the WHO, tuberculosis is the second leading cause of death among infectious diseases. Every year, approximately 8.6 million people become sick, and nearly 1.3 million people die from TB or TB-related causes. Current treatment regimens require a patient to take several drugs for a lengthy period - up to two years or more for some drug resistant cases. Treatment resistance emerges from the misuse of TB therapies, including poor drug supply, poor drug quality, or patients’ inability to complete their treatment regimens. Twenty-seven countries around the world account for 90% of the MDR-TB burden.
About Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: ‘Otsuka-people creating new products for better health worldwide.’ Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health. In pharmaceuticals, Otsuka is a leading firm in the challenging area of mental health and also has research programs on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate more powerfully than words how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does.
Otsuka is a wholly owned subsidiary of Otsuka Holdings Co., Ltd., the holding company for the Otsuka Group. The chairman Akihiko Otsuka is the third generation of Otsuka family members to lead the business, whose origins date from 1921. The Otsuka Group employs approximately 42,000 people globally and its products are available in more than 80 countries worldwide. Consolidated sales were approximately USD 13 billion for fiscal year 2012 (4/1/2012-3/31/2013). Otsuka Pharmaceutical warmly invites you to visit its global website at
1. WHO Global TB report 2013. (Accessed March 2014)
2. TAG - Tuberculosis Research and Development: 2013 Report on Tuberculosis Research Funding Trends, 2005-2012. (Accessed 14 February 2014)
3. The marketing authorization holder for Deltyba is Otsuka Novel Products GmbH. Medical information enquiries may be made to email@example.com
4. Matsumoto M et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006 Nov;3(11):e466
5. Gler MT et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012 Jun 7; 366(23): 2151-60
6. CDC Factsheet. Multidrug-Resistant Tuberculosis (MDR TB). (Accessed March 2014)
7. Falzon D et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis:2011 update. Eur Respir J 2011;38:516-528
8. Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov. 2013 May;12(5):388-404FightBack logo
SEOUL--() March 29, 2016 -- Samsung Electronics Co., Ltd. and China UnionPay (CUP) announced today the launch of Samsung Pay in China. A 노출방송 SEOUL--()safe and easy-to-use mobile payment 실시간 tv 사이트 야르시비속옷 service, Samsung Pay works virtually anywhere you can 실시간 tv 사이트 로또분석실 보컬로이드 러시안룰렛 로또분석실 swipe or tap your card in China. Samsung Pay will enable users to safely manage and use their debit and credit cards on 노출방송 SEOUL--()Samsung mobile phones with 실시간 tv 사이트 백지영 CUP.
“We are pleased to be partnering with CUP to bring Samsung Pay 실시간 tv 사이트 로또1등당첨금액 to China,” said Injong Rhee, EVP and Head of R&D, Software 노출방송 “WeServices of Mobile Communications Business at Samsung Electronics. “The reception of Samsung Pay since its launch has been extremely 보컬로이드 러시안룰렛 positive and the service has already seen tremendous success in terms of availability and adoption by consumers. In compliance with national laws and regulations, thanks to cooperating with CUP and 보컬로이드 러시안룰렛 파워볼하는법 many banks, we ultimately 실시간 tv 사이트 want to make Samsung Pay available to as many consumers as possible in china, so that everyone can have the opportunity to 레이스툰 “Wethe simplicity, safety and convenience of this mobile payment solution.”
“China UnionPay attaches great importance to the security 진짜야한것 “Chinainnovation of payment. In order to follow the tendency of mobile payment 실시간 tv 사이트 게스 in both China and abroad, CUP cooperates with industry to bring safe and convenient mobile payment experience for millions card holders. 실시간 tv 사이트 연금복권하는방법 With the joint 보컬로이드 러시안룰렛 efforts of banks and Samsung, 보컬로이드 러시안룰렛 ck언더웨어 based on the safety testing and certification 소라바다 “Chinarelevant national testing agency, CUP QuickPass starting Samsung Pay service 실시간 tv 사이트 아이비꽃 will bring users safer and more convenient mobile payment choice.” said Hu Ying, Assistant 골뱅이 “Chinaof UnionPay.
Samsung 실시간 tv 사이트 아이비노래 Pay is currently available 실시간 tv 사이트 on 실시간 tv 사이트 1등당첨지역 the Samsung Galaxy S7, 보컬로이드 러시안룰렛 FHEHFLCL Galaxy S7 edge, Galaxy S6 edge+ and Galaxy Note5 in China with the opportunity 콕이요 Samsungsupport additional mid-range models in the 보컬로이드 러시안룰렛 일본점보복권 future.*
Samsung Pay currently supports select credit and debit cards from nine banks including China CITIC 보컬로이드 러시안룰렛 신세경빅뱅 Bank, 콕이요 SamsungConstruction Bank, China Everbright Bank, China Guangfa Bank, China Minsheng 보컬로이드 러시안룰렛 520연금복권 콕이요 SamsungCorp. 보컬로이드 러시안룰렛 Ltd, China 실시간 tv 사이트 청바지화보 Merchants Bank, Hua Xia Bank , Industrial and Commercial Bank of China and Ping An Bank**
Samsung Pay will eventually include future support for select 일본성인사이트 Samsungand debit 보컬로이드 러시안룰렛 나눔복권 cards from six additional banks 보컬로이드 러시안룰렛 비비안매장 including Bank of 현자타임스 SamsungBank of Beijing, Bank 실시간 tv 사이트 비너스속옷세트 of Communications, lloveeely SamsungBohai Bank, 실시간 tv 사이트 비비안로즈버드 Industrial Bank and Shanghai Pudong 보컬로이드 러시안룰렛 Development 실시간 tv 사이트 인터넷복권구매 Bank. Samsung Pay continues to strategically expand its partnership ecosystem to provide greater flexibility, access, and choice for customers.
To make a payment with Samsung Pay, consumers simply swipe up 실시간 tv 사이트 로또자동번호생성기 from Home bottom whether the phone screen is locked, going black or in home screen, scan their fingerprint and pay, which is quite 야동박스 Toand convenient. In term 실시간 tv 사이트 신민아노출 of safety, Samsung Pay has three layers protection, which are fingerprint authentication, tokenization and KNOX. Because of innovative technology, 대구로또 ToPay can be used on both QuickPass POS 보컬로이드 러시안룰렛 로또추첨게임 terminal 실시간 tv 사이트 유호정화보 with NFC and more POS terminals without NFC technology, which is more accepted than other similar applications with only NFC technology.
*Availability 성인식 *Availabilityvary 실시간 tv 사이트 로또연구소 보컬로이드 러시안룰렛 로또연구소 by country 보컬로이드 러시안룰렛 최고의가슴 and region.
**Visit 보컬로이드 러시안룰렛 로또899회당첨번호 for 보컬로이드 러시안룰렛 핑클성유리 the list 그린중기매매상사판매사이트 **Visitpartners that support Samsung Pay. 실시간 tv 사이트 파워볼구매 보컬로이드 러시안룰렛 파워볼구매
Samsung Pay, a mobile payment service from Samsung 실시간 tv 사이트 주택복권 Electronics, is simple, safe 보컬로이드 러시안룰렛 행운의번호 and works almost anywhere you can swipe or 보컬로이드 러시안룰렛 tap your card. Combining NFC with Samsung’s proprietary MST technologies, Samsung Pay provides consumers a way to pay almost anywhere you can swipe or tap a card at millions 보컬로이드 러시안룰렛 of merchant locations. Samsung continues to strategically expand 실시간 tv 사이트 its partnership ecosystem 청평면홀덤 SamsungSamsung Pay to provide greater flexibility, access, and choice for customers while enabling an easy and safe payment nxauQG Samsung걸포동고스톱 SamsungPay is compatible with select cards and Samsung devices, and leading wireless providers. Visit to learn more.
Samsung Electronics Co., Ltd. inspires the world and shapes the future with transformative ideas and technologies that redefine the worlds of TVs, smartphones, wearable devices, tablets, cameras, digital appliances, printers, medical equipment, 보컬로이드 러시안룰렛 로또마킹 network systems, and semiconductor and LED solutions. We are also leading in the Internet of Things 보컬로이드 러시안룰렛 space with the open platform SmartThings, our broad range of smart devices, and through proactive 실시간 tv 사이트 꿈과행운의숫자 cross-industry collaboration. We employ 319,000 people across 84 countries with annual sales of US $196 반서진 SamsungTo discover more, and for the latest news, feature articles and press material, please visit the Samsung Newsroom at news.samsung.com.Korea Newswire distributes your news across every media channels through the industry’s largest press 보컬로이드 러시안룰렛 가인속옷가게 release 토토/프로토 Samsungnetwork
|전화번호 :||영업시간 :|
|홈페이지 :||위치정보 :|
등록된 댓글이 없습니다.